Table 2.
Prevalence of metabolic changes observed in Turner Syndrome patients along with different hormone replacement therapy regimens.
| Metabolic changes | N (total) | % | P-value | |
|---|---|---|---|---|
| A-Before HRT | ||||
| Hypertension | 4 (38) | 10.5 | ||
| Dysglycemia | 3 (28) | 10.7 | ||
| Dyslipidemia | 8 (23) | 34.8 | ||
| Overweight/ Obesity | 10 (43) | 23.2 | ||
| B-HRT with estrogen-only | A vs B | |||
| Hypertension | 6 (28) | 20.7 | 0.222 | |
| Dysglycemia | 2 (13) | 15.4 | 0.670 | |
| Dyslipidemia | 6 (12) | 50.0 | 0.383 | |
| Overweight/ Obesity | 13 (29) | 44.8 | 0.054 | |
| C-HRT with estrogen and within the first year of progestin | A vs C | |||
| Hypertension | 3 (25) | 12.0 | 0.855 | |
| Dysglycemia | 0 (19) | 0 | - | |
| Dyslipidemia | 9 (24) | 37.5 | 0.846 | |
| Overweight/ Obesity | 12 (29) | 41.3 | 0.101 | |
| D-HRT with estrogen and after long-term of progestin | A vs D | |||
| Time evaluated (years)* | 2.67 y (1.00 to 14.08 y) | |||
| Hypertension | 15 (59) | 25.4 | 0.071 | |
| Dysglycemia | 6 (59) | 10.2 | 0.937 | |
| Dyslipidemia | 18 (66) | 27.3 | 0.495 | |
| Overweight/Obesity | 43 (73) | 58.9 | 0.00019* | |
A and B, Phase 2.1, HRT before and after estrogen-only; C, Phase 2.2, HRT with estrogen and within one year of progestin. D, Phase 2.3, HRT with estrogen and long-term progestin. HRT, Hormone Replacement Therapy, *time evaluated as the average and minimum-maximum. In parenthesis is represented the number of patients with available data regarding that aspect analyzed.